Penn Medicine Provider
Endocrine and Oncologic Surgery
John T. Miura, MD
5.0
(502)
Accepting new patients
Sees patients age 18 and up
Penn Endocrine and Oncologic Surgery Perelman 3rd Floor
View 1 additional location
Make an appointmentCall 215-614-1963

About me

  • Assistant Professor of Surgery at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Medical College of Wisconsin
  • Residency: Medical College of Wisconsin
  • Fellowship: University of South Florida

What my patients think about me

Average Rating
5.0

504 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

August 2025
5.0
5.0
like him
July 2025
5.0
5.0
great experience
July 2025
5.0
5.0
wonderful md
July 2025
5.0
5.0
he's good

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Miura is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Vargas GM, Farooq MS, Shafique N, Lee MK, Vollmer CM, Miura JT, Karakousis GC. Impact of Patient Income and Insurance on Postoperative Mortality After Total Pancreatectomy for Pancreatic Neoplasms , J Surg Oncol: 2025

Brown LM, Wilkins SG, Bansal VV, Su DG, Gomez-Mayorga J, Turaga KK, Gunderson CG, Lee B, Nash GM, Hays JL, Raghav KP, Husain AL, Kluger MD, Zauderer MG, Kindler HL, Alexander HR; Peritoneal Surface Malignancies Consortium Group. Consensus guideline for the management of peritoneal mesothelioma , Cancer, 131: 2025,e35868

Godfrey EL, Mahoney F, Bansal VV, Su DG, Hanna DN, Lopez-Ramirez F, Baron E, Turaga KK, Benson AB, Cusack J, Winer JH, Gunderson CG, Misdraji J, Shah R, Magge DR, Solsky I, Eng C, Eng OS, Shergill A, Shen JP, Foote MB; Peritoneal Surface Malignancies Consortium Group. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement , Cancer, 131: 2025,e35867

Godfrey EL, Mahoney F, Bansal VV, Su DG, Hanna DN, Lopez-Ramirez F, Baron E, Turaga KK, Benson AB 3rd, Setia N, Winer JH, Gunderson CG, Shah R, Magge DR, Solsky I, Eng C, Eng OS, Shergill A, Shen JP, Misdraji J, Foote MB, Luo W; Peritoneal Surface Malignancies Consortium Group. Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement , Cancer, 131: 2025,e35874

Godfrey EL, Mahoney F, Bansal VV, Su DG, Hanna DN, Lopez-Ramirez F, Baron E, Turaga KK, Benson AB 3rd, Setia N, Winer JH, Gunderson CG, Shah R, Magge DR, Solsky I, Eng C, Eng OS, Shergill A, Shen JP, Misdraji J, Foote MB, Luo W; Peritoneal Surface Malignancies (PSM) Consortium Group. Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 2: Appendiceal Tumors with Peritoneal Involvement , Ann Surg Oncol: 2025

Godfrey EL, Mahoney F, Bansal VV, Su DG, Hanna DN, Lopez-Ramirez F, Baron E, Turaga KK, Benson AB 3rd, Cusack J, Winer JH, Gunderson CG, Misdraji J, Shah R, Magge DR, Solsky I, Eng C, Eng OS, Shergill A, Shen JP, Foote MB; Peritoneal Surface Malignancies (PSM) Consortium Group. Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 1: Appendiceal Tumors Without Peritoneal Involvement , Ann Surg Oncol: 2025

Brown LM, Wilkins SG, Bansal VV, Su DG, Gomez-Mayorga J, Turaga KK, Gunderson CG, Lee B, Nash GM, Hays JL, Raghav KP, Husain AL, Kluger MD, Zauderer MG, Kindler HL, Alexander HR; Peritoneal Surface Malignancies (PSM) Consortium Group. Consensus Guideline for the Management of Peritoneal Mesothelioma , Ann Surg Oncol: 2025

Farooq MS, Mattfeld V, Vargas GM, Shafique N, Miura JT, Karakousis GC. Recurrence patterns and survival outcomes in clinical stage IIB/IIC melanoma: Can we stratify patients for consideration of neoadjuvant immunotherapy? , Poster Presentation at the Ali Naji Research Day – University of Pennsylvania. May 7, 2025, Philadelphia, Pennsylvania. : 2025

Vargas GM, Farooq MS, Shafique N, Ming ME, Miura JT, Karakousis GC. Association between UV irradiation exposure by geographic region and stage at presentation in patients with melanoma. , Society of Investigative Dermatology Conference. May 9, 2025. Poster presentation.: 2025

Farooq MS, Ertmann E, Vargas GM, Shafique N, Mitchell TC, Schuchter LM, Amaravadi RK, Karakousis GC, Miura JT. Combination ipilimumab/nivolumab for refractory Merkel cell carcinoma: a single-institution experience. , Journal of Clinical Oncology: 2025